Alaunos Therapeutics, Inc. (TCRT)
$1.05+32.91%Close
SELLCRISIS · day 37
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3M
- Beta
- -0.97
- P/E (TTM)
- -0.38
- Short % float
- 0.52%
- Days to cover
- 1.0
- SI change
- +60.3%
- 1W
- +31.25%
- 1M
- -30.46%
- vs SPY 1W
- +30.83%
- vs SPY 1M
- -32.52%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-139.6%
REV YoY-
ROE-232.6%
EPS YoY-
ROA-264.5%
GROSS-28133
OP-135267
NET-133667
[VALUATION]
P/E TTM-0.38
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B2.77
P/FCF-
EV/EBITDA-0.42
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.77
ND/EBITDA-
BETA-0.97
Company news
FAQ
- What is LOPJLB’s current signal on TCRT?
- LOPJLB’s latest quantitative signal on Alaunos Therapeutics, Inc. (TCRT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TCRT in?
- Alaunos Therapeutics, Inc. (TCRT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alaunos Therapeutics, Inc. (TCRT) do?
- Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, …